We often see celebrities go through weight loss transformations, with side-by-side comparisons of the before and after weight loss. But people often do not feel inspired or drawn to their stories as we all know that they have access to great personal trainers, high-end food products as well as better access to healthcare. But one story that was highlighted by Men’s Health in their ‘First Steps’ series can inspire many with the story of Simon Lafontant, who lost 150 pounds and went on to become a body builder.

Simon Lafontant, a 32-year-old from Calgary, had to deal with some serious health problems for a long time. These included low testosterone and Crohn's disease, which made his life difficult. But Simon decided he wanted to make a change. He got medical help for his low testosterone and then set a big goal for himself: to compete in a bodybuilding competition. He used social media to keep himself on track, and he ended up losing over 150 pounds and even winning the competition! His story is about how he went from struggling with his health to becoming a bodybuilding champion.

How A Disease Can Become A Turning Point

Simon talks about how he used to have bad habits and wasn't living a healthy lifestyle. This led to him feeling down, gaining weight, and losing motivation. Things got really serious in 2020 when his Crohn's disease caused him to be in the hospital for seven whole months. According to Mayo Clinic Crohn’s disease is a type of inflammatory bowel disease that is inflammation in your digestive tract which can be very painful and can cause people to need long term remission and time to heal the inflammation. Simon spoke about how he realized his poor lifestyle choices and being obese had made his symptoms worse!

While you may not wish to become a bodybuilder, there are many other aspects you can take away from the Simon’s story! Another trip to the doctors revealed that he had very low testosterone levels, which explained his lack of energy. This was a major turning point for him, as he finally understood some of the reasons behind his struggles.

What Role Does Testosterone Play?

One thing that made a huge difference in Simon’s weight loss journey was getting the TRT treatment for his low testosterone which had an almost immediate effect on him. He felt good, started enjoying things again, like going outside and working out. He also remembered how much he loved powerlifting and Strongman competitions, so this helped him get on to his path to bodybuilding and weight training!

Low testosterone affects both men and women, but in different ways. In women, it can cause low sex drive, tiredness, muscle weakness, trouble getting pregnant, irregular periods, vaginal dryness, mood changes like depression or anxiety, hair thinning, dry skin, and sleep problems. In men, low testosterone can lead to reduced sex drive, erectile dysfunction, hair loss, smaller testicles, hot flashes, and infertility. Other symptoms in men include feeling down, trouble concentrating or remembering things, and increased body fat. If you're experiencing any of these symptoms, it's a good idea to talk to a doctor.

Eli Lilly's experimental weight-loss drug retatrutide, being referred to as ‘Godzilla’, continues to outperform its rivals like Ozempic.

According to a recent head-to-head Phase 3 clinical trial involving adults with type 2 diabetes, it delivered more than twice the average weight loss achieved with Ozempic.

Ozempic Vs Retatrutide

Participants who took the highest dose of retatrutide lost an average of 20.9% of their body weight over 80 weeks, compared to 9.4% among those receiving Ozempic's highest approved dose for type 2 diabetes.

The trial, called TRANSCEND-T2D-2, involved more than 1,000 adults with type 2 diabetes. It compared once-weekly injections of retatrutide at doses of 9 mg and 12 mg with semaglutide, the active ingredient in Ozempic, at 2 mg.

At the end of 80 weeks, participants taking retatrutide 9 mg lost an average of 44.3 pounds (20.1 kg), while those receiving the 12 mg dose lost 47.4 pounds (21.5 kg). The Ozempic group lost an average of 20.9 pounds (9.5 kg).

The findings mark the first Phase 3 head-to-head comparison of retatrutide with another medicine in this class.

Also read: ‘Godzilla’ Drug Retatrutide Reverses Sleep Apnea In 1 In 4 Diabetes Patients

Retatrutide Also Improved Blood Sugar

The trial found that retatrutide also resulted in produced greater reductions in HbA1c, a measure of average blood glucose over approximately three months.

At 80 weeks, participants taking either dose of retatrutide recorded an average HbA1c reduction of 2.2%, compared to 1.8 % among those receiving Ozempic.

The experimental drug also resulted in greater improvements in cardiovascular risk factors like non-HDL cholesterol, triglycerides and systolic blood pressure.

Also read: Could GLP-1 Drugs Help Prevent Rupture Of Abdominal Aortic Aneurysm? Study Finds 46% Reduction In Risk

Side Effects Of Retatrutide

The most commonly reported side effects of retatrutide were gastrointestinal symptoms like diarrhoea, nausea, constipation, vomiting and indigestion.

Diarrhoea was reported in 28.3% of participants receiving the 9 mg dose and 32.7% receiving 12 mg, compared to 26.4% in the Ozempic group. Nausea occurred in 21.2%, 23.8% and 21.3% of participants, respectively.

Researchers also reported a higher incidence of dysesthesia, an abnormal sensation that can include tingling, burning or skin sensitivity, among participants taking retatrutide.

Treatment discontinuation because of side effects occurred in 4.8% of the 9 mg group and 7.9% of the 12 mg group, compared to 2.7% of the Ozempic group.

More About Retatrutide

Retatrutide is a once-weekly injectable drug that targets three hormone receptors involved in regulating appetite, blood sugar and metabolism. They are GLP-1, GIP and glucagon.

GLP-1 helps regulate appetite and blood sugar while slowing the process of stomach emptying. GIP also plays a role in glucose regulation and insulin release. Glucagon is involved in controlling blood glucose and energy metabolism.

Ozempic, manufactured by Novo Nordisk, acts on the GLP-1 receptor. Eli Lilly's Mounjaro and Zepbound, which contain tirzepatide, target both GLP-1 and GIP receptors.

Retatrutide remains an investigational drug and has not been approved by the US Food and Drug Administration (FDA) or other regulatory authorities.

Eli Lilly plans to submit the drug for FDA approval in early 2027. The company said detailed results from the trial would be presented at a future medical meeting and published in a peer-reviewed journal.

The hype around GLP-1 weight loss drugs keeps growing due to numerous new benefits as well as side effects that are discovered every other day. A recent study found that the risk of aortic aneurysm rupture is significantly less among GLP-1 users. The study was published in the Journal of Vascular Surgery.

GLP-1 receptor agonists is a a class of medicines that is widely used to treat type 2 diabetes and obesity. Users have reported substantial weight loss results with the help of these medicines like Ozempic, Mounjaro, Zepbound and others.

Now, researchers have found that people with abdominal aortic aneurysms who used GLP-1 drugs had a 46% lower risk of rupture over five years compared with those who did not use these medicines. This means that GLP-1 drugs may also have cardiovascular benefit apart from diabetes and obesity.

The study analysed health records from 123 healthcare organisations in the US. It is based on more than 412,000 people diagnosed with abdominal aortic aneurysms who underwent imaging surveillance every six months.

After matching patients based on factors like age, sex, diabetes, high blood pressure, smoking, heart disease and kidney disease, the researchers compared 13,722 GLP-1 receptor agonist users with an equal number of non-users.

GLP-1 Drugs Linked To Fewer Aortic Aneurysm Ruptures

Also read: ‘Godzilla’ Drug Retatrutide Reverses Sleep Apnea In 1 In 4 Diabetes Patients

After five years, aortic aneurysm rupture was recorded in about 1.6% of people taking GLP-1 drugs, compared to 2.4% of those who were not taking them.

The researchers reported a hazard ratio of 0.538, indicating a 46.2% lower risk of rupture among GLP-1 drug users after adjustment.

The difference was also observed at the two-year mark, when rupture occurred in 1.1% of GLP-1 users compared to 1.8% of non-users.

People taking GLP-1 drugs also had fewer elective aneurysm repairs. At five years, 2.1% of users underwent elective repair compared to 3% of non-users.

The study further found lower rates of major cardiovascular events like heart attacks, strokes and heart failure, as well as lower all-cause mortality among GLP-1 users.

What Is An Abdominal Aortic Aneurysm?

Also read: The Changing Obesity Treatment Landscape: Where Does Bariatric Surgery Fit in the Age of Weight-Loss Drugs?

An abdominal aortic aneurysm (AAA) occurs when a section of the aorta, the body's largest artery, becomes enlarged or bulges due to weakening of its wall. It develops in the part of the aorta that passes through the abdomen.

Many abdominal aortic aneurysms do not cause symptoms and are detected during tests. However, as the aneurysm enlarges, its risk of rupture increases.

A ruptured aneurysm is considered to be a medical emergency as it can cause severe internal bleeding. Symptoms may include sudden, severe abdominal or back pain, dizziness, fainting and a rapid heartbeat.

Smoking, older age, high blood pressure, atherosclerosis and a family history of aneurysms are among the risk factors.

GLP-1 Drugs & Lower Risk Of Aortic Aneurysm Rupture Risk

GLP-1 receptor agonists work by mimicking the naturally occurring GLP-1 hormone. They help regulate blood sugar by stimulating insulin release when glucose levels are high, slowing the emptying of stomach and reducing appetite.

Some of their effects may also impact blood vessel health. Abdominal aortic aneurysms develop through several processes, including inflammation, damage to vascular smooth muscle cells and changes in the proteins that maintain the artery wall.

GLP-1 drugs have shown anti-inflammatory and cardiovascular benefits in older research. The researchers suggest these effects may help explain the lower rates of aneurysm-related complications observed in the study.

The findings are promising but do not conclusively prove that GLP-1 medicines prevent aneurysm rupture. This was a retrospective observational study, meaning researchers examined existing health records rather than randomly assigning patients to receive the drugs.

One important limitation was that aneurysm size was not included among the matching variables. Since aneurysm size is a major determinant of rupture risk, differences between the groups could have impacted the findings.

When a woman misses her period, pregnancy is usually the first thing she thinks about. If that is ruled out, stress, weight changes or a hormonal imbalance may seem like the obvious explanations. But when periods become irregular or stop for several months, there may be more to the story.

In some women, these changes can also signal a risk to bone health. The menstrual cycle is controlled by a complex interaction between the brain and the ovaries. Oestrogen, one of the key hormones involved, is important not only for reproductive health but also for maintaining strong bones. It helps regulate the continuous process of bone breakdown and rebuilding.

When oestrogen levels remain low for a prolonged period, this balance can be disturbed, leading to a reduction in bone mineral density and, in some cases, an increased risk of fractures.

Menstrual health is not just about getting a period every month. It can offer important clues about what is happening elsewhere in the body.

Why Do Periods Sometimes Stop?

Also read: Why Do My Breasts Hurt Right Before My Period?

One possible cause is functional hypothalamic amenorrhoea, a condition in which the brain reduces the hormonal signals that stimulate the ovaries. It may occur when the body is under physical or emotional stress, particularly in the setting of inadequate food intake, rapid weight loss, excessive exercise or a combination of these factors.

In simple terms, the body may not be getting enough energy to support all its normal functions. Reproductive activity can slow down as a result. If this continues, the effects may extend beyond the menstrual cycle.

Low energy availability can affect hormones involved in bone formation and maintenance. Inadequate intake of protein, calcium and vitamin D may further compromise bone health.

The concern is particularly important in adolescents and young women, because these are the years when the body builds much of its peak bone mass. If this process is disrupted, they may not achieve their full bone-strength potential, which can have implications for bone health later in life. It can happen even when a woman is not underweight.

One common misconception is that only very thin women are at risk. In reality, a woman can have a seemingly healthy body weight and still not be eating enough to meet the demands of her daily activity.

A student under academic pressure may skip meals regularly. A working professional may combine long hours with restrictive eating, while a woman who exercises intensively may not increase her food intake to match her energy needs. In such situations, menstrual changes may be one of the first noticeable signs that something is wrong.

Persistent tiredness, declining exercise performance, poor recovery after workouts and recurrent bone or muscle injuries may provide additional clues.

These symptoms are easy to dismiss as the result of a busy lifestyle, but they deserve attention when they occur alongside irregular or absent periods.

Not Every Missed Period Has The Same Cause

Also read: Women With Endometriosis Are Earning Less, Reveals Study

Although inadequate energy intake and prolonged stress can affect menstruation, they are not the only explanations. Pregnancy must first be ruled out. Other possible causes include polycystic ovary syndrome (PCOS), thyroid disorders, raised prolactin levels, premature ovarian insufficiency, chronic illnesses and certain medications.

A woman should seek medical evaluation if her periods stop for three months without an explanation, if her cycles remain persistently irregular, or if menstrual changes are accompanied by significant weight loss, restrictive eating, excessive exercise, bone pain or a stress fracture.

The assessment usually begins with a detailed menstrual history and questions about diet, exercise, weight changes, stress and medication use. Depending on the findings, the doctor may recommend pregnancy testing, blood tests to assess thyroid function and reproductive hormones, prolactin levels and other investigations.

A bone mineral density scan may also be appropriate when periods have been absent for a prolonged period or when additional risk factors for bone loss are present.

Protecting Menstrual Health Also Means Protecting Bone Health

Treatment depends on the underlying cause. When inadequate energy availability is responsible, the priority is to restore a healthy balance between food intake, physical activity and recovery.

This may require nutritional guidance, changes to exercise routines and support for managing psychological stress. A gynaecologist may work with an endocrinologist, dietitian or mental-health professional, depending on the individual’s needs.

Adequate calcium, vitamin D and protein are important for bone health, but supplements alone cannot correct an ongoing energy deficit. Similarly, hormonal medication should not be prescribed simply to produce a period without first understanding why menstruation has stopped.

A menstrual cycle is more than a monthly reproductive event. Persistent changes can provide valuable clues about hormonal function, nutrition and overall health. Paying attention to these changes early can help identify underlying problems and, where necessary, protect bone health for the future.